PedAM
Pediatric Disease Annotations & Medicines
| Disease | down syndrome |
| Phenotype | C0023418|leukemia |
| Sentences | 31 |
| PubMedID- 24391118 | Outcome of transplantation for acute lymphoblastic leukemia in children with down syndrome. |
| PubMedID- 22150305 | Myeloid leukemia in down syndrome. |
| PubMedID- 26481183 | Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in down syndrome: a nationwide prospective study in japan. |
| PubMedID- 25545182 | Neuropsychological late effects of treatment for acute leukemia in children with down syndrome. |
| PubMedID- 25887863 | Transient abnormal myelopoiesis (tam) and myeloid leukemia associated with down syndrome (ml of ds) have morphologically indistinguishable blasts. |
| PubMedID- 20007548 | The transient myeloproliferative disorder and acute megakaryocytic leukemia associated with down syndrome are uniquely associated with mutations in the transcription factor gata1; however, the identity of trisomic genes on chromosome 21 that predispose to these hematologic disorders remains unknown. |
| PubMedID- 22110660 | down syndrome (ds) children with leukemia exhibit some of the most unique biological and therapeutic features of leukemia. |
| PubMedID- 22281466 | Cases of malignant tumors other than leukemia, which are associated with down syndrome, are extremely rare. |
| PubMedID- 24991719 | There were 42 cases of congenital leukemia associated with down syndrome (ds) and 39 of these cases presented features of acute myeloid leukemia (aml)-m7. |
| PubMedID- 23980066 | Development of acute megakaryoblastic leukemia in down syndrome is associated with sequential epigenetic changes. |
| PubMedID- 22392565 | Favorable survival maintained in children who have myeloid leukemia associated with down syndrome using reduced-dose chemotherapy on children's oncology group trial a2971: a report from the children's oncology group. |
| PubMedID- 22937757 | In particular, the somatic mutation of the gata1 gene, which leads to the production of n-terminally truncated gata1, contributes to the genesis of transient myeloproliferative disorder and acute megakaryoblastic leukemia in infants with down syndrome. |
| PubMedID- 22776818 | Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with down syndrome. |
| PubMedID- 20692111 | [fetal hepatosplenomegaly in the third trimester: a sign of leukemia in fetuses with down syndrome]. |
| PubMedID- 24222333 | Acute lymphoblastic leukemia in children with down syndrome: a retrospective analysis from the ponte di legno study group. |
| PubMedID- 23467128 | Outcome of transplantation for acute myelogenous leukemia in children with down syndrome. |
| PubMedID- 20595099 | Acute leukemia in children with down syndrome. |
| PubMedID- 23874683 | Furthermore, pediatric down syndrome (ds) patients with acute megakaryocytic leukemia (amkl), whose blast cells almost universally harbor somatic mutations in exon 2 of the transcription factor gene gata1, demonstrate increased overall survival relative to non-ds pediatric patients, suggesting a potential role for gata1 in chemotherapy response. |
| PubMedID- 24744653 | Although it was reported that jak2 v617f mutation is absent in childhood all, rare mutations have been reported, especially in down syndrome patients with acute leukemia [4,5,6,7,8,9]. |
| PubMedID- 25499068 | Immune-related conditions and acute leukemia in children with down syndrome: a children's oncology group report. |
| PubMedID- 25231553 | Prognosis and management of acute myeloid leukemia in patients with down syndrome. |
| PubMedID- 22113227 | Hematological disorders and leukemia in children with down syndrome. |
| PubMedID- 22072402 | High frequency of btg1 deletions in acute lymphoblastic leukemia in children with down syndrome. |
| PubMedID- 25932450 | A case of pentasomy 21 with two isochromosome 21s in acute megakaryoblastic leukemia associated with down syndrome. |
| PubMedID- 22942569 | Transient leukemia in down syndrome: report of two cases with review of literature. |
| PubMedID- 20113894 | Myeloid leukemia in children with down syndrome is preceded by a preleukemic clone (transient leukemia or transient myeloproliferative disorder), which may disappear spontaneously, but may also need treatment in case of severe symptoms. |
| PubMedID- 20418240 | Methotrexate clearance was 5% lower in the acute lymphoblastic leukemia patients with down syndrome (p=0.001); however, this small difference is probably clinically not relevant, because no significant differences in methotrexate plasma levels were detected at 24 and 48 hours. |
| PubMedID- 24962331 | Background: most down syndrome children with acute myeloid leukemia (ds-aml) have an overall excellent prognosis, however, patients who suffer an induction failure or relapse, have an extremely poor prognosis. |
| PubMedID- 22459425 | Solid mass tumors are not as common as leukemia in individuals with down syndrome. |
| PubMedID- 25587735 | Approximately 20%-30% of tam survivors are at risk of development of acute myeloid leukemia (myeloid leukemia associated with down syndrome, ml-ds). |
| PubMedID- 21557456 | Background: the aim of the jcclsg aml 9805 down study was to evaluate the effect of continuous and high-dose cytarabine combined chemotherapy on the survival outcome of acute myeloid leukemia (aml) with down syndrome (ds). |
Page: 1